A working-level guide to real estate accounting, covering client segments, ASC standards, tax structure, and
5 min read
Tax Byte
The DEA has begun the process to reclassify marijuana from a Schedule I drug (like heroin and LSD) to a Schedule III drug (like ketamine and anabolic steroids.) The proposal does not legalize recreational marijuana use, but it recognizes cannabis as a less dangerous drug and acknowledges its medical uses.
The move represents the DEA’s biggest policy shift in decades, and it’s likely to have far-reaching business and tax implications.
What are the tax and accounting implications of marijuana rescheduling?
Under Section 280E of the Internal Revenue Code, businesses involved in “trafficking” Schedule I and II substances may not claim deductions for what would otherwise be ordinary business expenses, such as payroll, marketing costs, and rent. As such, reclassifying marijuana as a Schedule III drug will drastically lower the tax obligations of cannabis businesses. It will also help cannabis businesses that are legal at the state level better compete with competitors who operate illegally.
Recent Stories
Alert Your Business Clients to 2026 Form W-2 Changes for OBBBA
January 23, 2026
Trump Executive Order Directs Cannabis Rescheduling
January 19, 2026
Next Up...
Five practical steps tax professionals can use to guide clients through succession planning
6 min read
Five essential tips for financial planning professionals to help guide parents through financial planning for
7 min read